PARSIPPANY, N.J., Feb. 13 /PRNewswire/ -- Ferring Pharmaceuticals has launched the first Ferring Research Infertility and Gynaecology GrAnt (FRIGGA) for fundamental fertility and gynaecology research. This is an international, themed, biennial initiative open to individual researchers or research units/departments with the first awarded research projects to be completed by January 2010.
Professor Paul Devroey, Free University Brussels, will lead the international expert judging panel for FRIGGA. Two grants to the value of euros 50,000 each will be awarded with the announcement of first recipients of the awards at the European Society of Human Reproduction and Embryology (ESHRE) congress in Barcelona (6 - 9 July 2008). The deadline for the submission of grant applications is 30 April 2008.
The award is named after Frigga, the goddess of fertility, motherhood, love, family and home from Scandinavian mythology. This name encapsulates both the objective of infertility research and treatment -- parenthood -- and echoes the company's Scandinavian roots. The theme for the 2008 award is fundamental research leading to an increased understanding of the role of human chorionic gonadotrophin (hCG) in assisted reproduction.
Mr. Michel Pettigrew, Chief Operating Officer at Ferring said, "We are committed to taking the lead in the field of assisted reproductive technologies (ART) and the launch of FRIGGA reflects this commitment. We look forward to innovative research carried out through the FRIGGA award that will increase our understanding of infertility and that in the future will help infertile couples around the world achieve their goal."
In announcing the theme of the 2008 award, Paul Devroey, comments "We
have made great progress in the treatment of infertility in what is quite a
short period of time for medicine. If, however, we are to meet the growing
needs for treatment and the growing expectation of treatment standards, we
need to prog
|SOURCE Ferring Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved